Grants per year
Personal profile
Research Interests
My research interests revolve around understanding the risk factors, including host genetic risk, and improving outcomes of critically ill patients with serious infections. This includes severe community-acquired pneumonia, sepsis of all causes, and nosocomial infections, particularly ventilator-associated pneumonia.
Certifications and Licenses
| Internal Medicine | |
| Critical Care Medicine | |
| Pulmonary Disease |
Training Experience
| 1983 | Residency, Butterworth Hospital |
| 1985 | Fellowship, Henry Ford Hospital |
Education/Academic qualification
Medicine, MD, Indiana University
… → 1980
Research interests keywords
- Critical Care
- Critical Care Outcomes
- Genetics: Medical
- Pneumonia
Fingerprint
Dive into the research topics where Richard G Wunderink is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Prot #EGL-6535-C-2202: A Randomized, Double-Blind, Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of CAL02 Administered Intravenously in Addition to Standard of Care in Subjects with Severe Community-Acquired Bacterial Pneumonia
InClin, Inc., Eagle Pharmaceuticals, Inc.
3/22/23 → 3/22/26
Project: Research project
-
Successful Clinical Response In Pneumonia Therapy (SCRIPT) Systems Biology Center
Wunderink, R. G., Wunderink, R. G., Abdala-Valencia, H., Budinger, G. S., Budinger, G. S., Etemadi, M., Hartmann, E. M., Hultquist, J. F., Lorenzo Redondo, R., Luo, Y., Misharin, A., Morales-Nebreda, L., Ozer, E. A., Pickens, C. I., Qi, C., Scholtens, D. M., Singer, B., Stoeger, T., Swaminathan, S., Walter, J. M., Wunderink, R. G., Amaral, L. A. N., Budinger, G. S., Hartmann, E. M., Hauser, A. R., Misharin, A., Ozer, E. A., Pickens, C. I., Qi, C., Singer, B., Starren, J., Stoeger, T., Walter, J. M. & Wunderink, R. G.
National Institute of Allergy and Infectious Diseases
1/1/23 → 12/31/27
Project: Research project
-
Systems-based pharmacologic modeling to elucidate beta-lactam clinical pharmacodynamics and define optimal dosing regimens in severe pneumonia
Wunderink, R. G., Wunderink, R. G., Hauser, A. R., Hauser, A. R., Ozer, E. A. & Ozer, E. A.
Midwestern University, National Institute of Allergy and Infectious Diseases
7/11/22 → 6/30/27
Project: Research project
-
An Adjudication Protocol for Severe Pneumonia
The NU SCRIPT Study Investigators, Jul 1 2023, In: Open Forum Infectious Diseases. 10, 7, ofad336.Research output: Contribution to journal › Article › peer-review
Open Access -
Bronchoscopy for diagnosis of ventilator-associated pneumonia
Martin-Loeches, I., Chastre, J. & Wunderink, R. G., Jan 2023, In: Intensive Care Medicine. 49, 1, p. 79-82 4 p.Research output: Contribution to journal › Comment/debate › peer-review
Open Access2 Scopus citations -
Clinical Features of COVID-19 and Differentiation from Other Causes of CAP
Gao, C. A., Pickens, C. I., Morales-Nebreda, L. & Wunderink, R. G., Feb 2023, In: Seminars in Respiratory and Critical Care Medicine. 44, 1, p. 8-20 13 p.Research output: Contribution to journal › Article › peer-review
-
Clinical significance of culture-negative, PCR-positive bronchoalveolar lavage results in severe pneumonia
Rabin, E. E., Walter, J. M., Wunderink, R. G., Qi, C. & Pickens, C. I., Nov 1 2023, In: ERJ Open Research. 9, 6, 00343-2023.Research output: Contribution to journal › Letter › peer-review
Open Access -
Correction: ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia (Intensive Care Medicine, (2023), 49, 6, (615-632), 10.1007/s00134-023-07033-8)
Martin-Loeches, I., Torres, A., Nagavci, B., Aliberti, S., Antonelli, M., Bassetti, M., Bos, L. D., Chalmers, J. D., Derde, L., De Waele, J., Garnacho-Montero, J., Kollef, M., Luna, C. M., Menendez, R., Niederman, M. S., Ponomarev, D., Restrepo, M. I., Rigau, D., Schultz, M. J., Weiss, E., & 2 others, Aug 2023, In: Intensive Care Medicine. 49, 8, p. 1040-1041 2 p.Research output: Contribution to journal › Comment/debate › peer-review
Open Access
Datasets
-
Impact of Multiple Daily Clinical Pharmacist-Enforced Assessments on Time in Target Sedation Range
Lizza, B. D. (Creator), Jagow, B. (Creator), Hensler, D. (Creator), Cooper, C. J. (Creator), Short, E. J. (Creator), Maas, M. B. (Creator), Naidech, A. M. (Creator), Wunderink, R. G. (Creator) & Wunderink, R. G. (Creator), figshare, 2017
DOI: 10.25384/sage.c.4232345.v1, https://figshare.com/collections/Impact_of_Multiple_Daily_Clinical_Pharmacist-Enforced_Assessments_on_Time_in__Target_Sedation_Range/4232345/1
Dataset
-
Ceftolozane/tazobactam versus meropenem in patients with ventilated hospital-acquired bacterial pneumonia: subset analysis of the ASPECT-NP randomized, controlled phase 3 trial
Timsit, J. (Creator), Huntington, J. A. (Creator), Wunderink, R. G. (Creator), Shime, N. (Creator), Kollef, M. H. (Creator), Kivistik, Ü. (Creator), Nováček, M. (Creator), Réa-Neto, Á. (Creator), Martin-Loeches, I. (Creator), Yu, B. (Creator), Jensen, E. H. (Creator), Butterton, J. R. (Creator), Wolf, D. J. (Creator), Rhee, E. G. (Creator), Bruno, C. J. (Creator) & Timsit, J. (Creator), figshare, 2021
DOI: 10.6084/m9.figshare.c.5556746.v1, https://springernature.figshare.com/collections/Ceftolozane_tazobactam_versus_meropenem_in_patients_with_ventilated_hospital-acquired_bacterial_pneumonia_subset_analysis_of_the_ASPECT-NP_randomized_controlled_phase_3_trial/5556746/1
Dataset
-
-
Initiating angiotensin II at lower vasopressor doses in vasodilatory shock: an exploratory post-hoc analysis of the ATHOS-3 clinical trial
Wieruszewski, P. M. (Creator), Bellomo, R. (Creator), Busse, L. W. (Creator), Ham, K. R. (Creator), Zarbock, A. (Creator), Khanna, A. K. (Creator), Deane, A. M. (Creator), Ostermann, M. (Creator), Wunderink, R. G. (Creator), Boldt, D. W. (Creator), Kroll, S. (Creator), Greenfeld, C. R. (Creator), Hodges, T. (Creator), Chow, J. H. (Creator), Bellomo, R. (Creator), Wunderink, R. G. (Creator) & Kroll, S. (Creator), figshare, 2023
DOI: 10.6084/m9.figshare.c.6634033.v1, https://springernature.figshare.com/collections/Initiating_angiotensin_II_at_lower_vasopressor_doses_in_vasodilatory_shock_an_exploratory_post-hoc_analysis_of_the_ATHOS-3_clinical_trial/6634033/1
Dataset
-
Outcomes in participants with ventilated nosocomial pneumonia and organ failure treated with ceftolozane/tazobactam versus meropenem: a subset analysis of the phase 3, randomized, controlled ASPECT-NP trial
Martin-Loeches, I. (Creator), Shorr, A. F. (Creator), Wunderink, R. G. (Creator), Kollef, M. H. (Creator), Timsit, J. (Creator), Yu, B. (Creator), Huntington, J. A. (Creator), Jensen, E. (Creator), Bruno, C. J. (Creator), Wunderink, R. G. (Creator) & Timsit, J. (Creator), figshare, 2023
DOI: 10.6084/m9.figshare.c.6583244.v1, https://springernature.figshare.com/collections/Outcomes_in_participants_with_ventilated_nosocomial_pneumonia_and_organ_failure_treated_with_ceftolozane_tazobactam_versus_meropenem_a_subset_analysis_of_the_phase_3_randomized_controlled_ASPECT-NP_trial/6583244/1
Dataset